← Medtronic overview

Medtronic vs Stryker: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Medtronic PLC (MDT)

Q3 2026
▲3▼1

Medtronic Q3: Upgrades, Strong Sales, New Products, But Recalls and Tariffs Linger

  • UBS Upgrade and Strong Q1 Results UBS upgraded Medtronic to Buy, and Q1 revenue jumped 13.7% to $9.8 billion with raised guidance. Fiscal 2026 growth hit a decade-high 8.4%, showing broad business strength.

    This point highlights the positive analyst action and strong financial performance that drove the stock.

  • New Product Approvals and Acquisitions Medtronic won permanent reimbursement for renal denervation, completed the SPR Therapeutics acquisition, launched AI surgical tools, and gained FDA clearance for LigaSure on Hugo, expanding its product portfolio.

    These new products and deals are key growth drivers that can boost future revenue and investor confidence.

  • MiniMed Spin-Off Medtronic moved to spin off its diabetes unit MiniMed, a strategic move to focus on core businesses and unlock value for shareholders.

    The spin-off is a significant corporate action that could improve Medtronic's focus and valuation.

  • Recalls, Tariffs, and Lawsuits Medtronic faced a Class II Octopus 4 recall, $74 million in quarterly tariff costs (~$250 million annually), and an $88 million hernia mesh verdict with 2,400+ lawsuits pending, creating ongoing financial and reputational risks.

    These negative events weigh on the stock and represent real challenges that could pressure future earnings.

September 2026
▲3

Medtronic's strong quarter and new diabetes spin-off drive analyst optimism

  • FDA clears LigaSure for Hugo robotic surgery system Medtronic won FDA clearance to use its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. This makes Hugo more attractive to hospitals and helps Medtronic compete with Intuitive Surgical and Johnson & Johnson, supporting future sales growth.

    New regulatory approval expands the Hugo ecosystem and addresses competition in robotic surgery.

  • Medtronic launches exchange offer to spin off MiniMed diabetes unit Medtronic launched an exchange offer to split off at least 80.1% of its MiniMed diabetes business, offering shareholders a 7% discount. This simplifies the company and could unlock value, though the diabetes unit's future performance remains uncertain.

    New corporate action that could reshape Medtronic's business and investor perception.

  • Analyst price-target hikes follow Q1 beat, but ratings split After Medtronic's strong Q1 results, analysts raised price targets, with some seeing more upside and others staying neutral. Hedge funds increased stakes and short interest fell, suggesting growing confidence, but the debate over a re-rating continues.

    New analyst actions and positioning data show market reaction to the quarter and future outlook.

Latest
▲3

Medtronic's strong quarter and new diabetes spin-off drive analyst optimism

  • FDA clears LigaSure for Hugo robotic surgery system Medtronic won FDA clearance to use its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. This makes Hugo more attractive to hospitals and helps Medtronic compete with Intuitive Surgical and Johnson & Johnson, supporting future sales growth.

    New regulatory approval expands the Hugo ecosystem and addresses competition in robotic surgery.

  • Medtronic launches exchange offer to spin off MiniMed diabetes unit Medtronic launched an exchange offer to split off at least 80.1% of its MiniMed diabetes business, offering shareholders a 7% discount. This simplifies the company and could unlock value, though the diabetes unit's future performance remains uncertain.

    New corporate action that could reshape Medtronic's business and investor perception.

  • Analyst price-target hikes follow Q1 beat, but ratings split After Medtronic's strong Q1 results, analysts raised price targets, with some seeing more upside and others staying neutral. Hedge funds increased stakes and short interest fell, suggesting growing confidence, but the debate over a re-rating continues.

    New analyst actions and positioning data show market reaction to the quarter and future outlook.

August 2026
▲2▼2

Medtronic surges on record revenue, upgrade, and strong Q1

  • UBS upgrade and record revenue growth UBS upgraded Medtronic to Buy, citing a turnaround, and the company reported its highest annual revenue growth in a decade, with fiscal 2026 revenue up 8.4% to $36.4 billion. This signals improving fundamentals and boosts investor confidence.

    This point captures the key positive developments that drove the stock during the period.

  • Strong Q1 beat and raised guidance Fiscal Q1 revenue jumped 13.7% to $9.8 billion, beating estimates, and management raised full-year guidance. Cardiac Ablation Solutions surged 88%, showing broad-based strength and supporting a higher stock price.

    This point highlights the strong quarterly performance and raised outlook that positively impacted the stock.

  • Tariff costs and hernia mesh litigation Medtronic absorbed $74 million in tariff costs, with about $250 million expected annually, pressuring margins. An $88 million hernia mesh verdict leaves over 2,400 lawsuits pending, creating legal uncertainty that could weigh on the stock.

    This point addresses the significant headwinds that partially offset the positive momentum.

  • Competitive pressure in key markets Competitive pressure in cardiovascular and diabetes, including Abbott's new device, could limit upside despite the core business growing. This competition may slow Medtronic's market share gains and cap revenue growth.

    This point highlights the competitive challenges that could restrain future performance.

▲3▼1

Medtronic beats Q1, raises guidance on heart device strength

  • Q1 beat and raised guidance Medtronic reported fiscal Q1 revenue of $9.8 billion, up 13.7%, and adjusted EPS of $1.45, beating estimates. It raised full-year organic growth guidance to 7.25%-7.75% and EPS to $5.94-$6.00. This shows the business is growing faster than expected, which lifts the stock.

    This is the main new event that directly moves MDT's price.

  • Cardiac Ablation Solutions surge Cardiac Ablation Solutions grew 88% worldwide, and Cardiac Rhythm Management rose 15%. These heart-related products are driving most of the growth. Continued strength here supports the stock because it shows Medtronic is winning in a key market.

    It explains the underlying driver of the strong quarter and future growth.

  • Strategic deals and partnerships Medtronic completed acquisitions of Scientia Vascular and SPR Therapeutics, announced a partnership with Cornerstone Robotics, and invested in Pi-Cardia. These moves expand its product pipeline and technology, which can support future growth and investor confidence.

    New deals signal long-term growth potential beyond the current quarter.

  • Tariff costs and competition Medtronic expects $250 million in annual tariff costs, with $75 million hitting Q1. Also, Abbott's new diabetes device adds competition. These are real headwinds that could pressure profits and limit upside, even as the core business grows.

    It provides a fair counterweight to the positive earnings news.

▼3▲1

Medtronic's strong growth and UBS upgrade offset by tariff and legal headwinds

  • UBS upgrade and strong revenue growth UBS upgraded Medtronic to Buy, citing a turnaround. The company reported its highest annual revenue growth in a decade, with fiscal 2026 revenue up 8.4% to $36.4 billion, driven by a 78% surge in Cardiac Ablation Solutions. This positive momentum could attract more investors and push the stock higher.

    This is a new positive development that directly boosts investor confidence and the stock's outlook.

  • Tariff headwinds Medtronic absorbed a $74 million tariff impact in the latest quarter and expects roughly $250 million in fiscal 2027. These tariffs increase costs and could pressure profit margins, potentially weighing on the stock price.

    This is a new negative factor that affects future profitability and is a key concern for investors.

  • Hernia mesh lawsuit verdict A federal jury ordered Medtronic to pay $88 million in the first Covidien hernia mesh bellwether trial, with over 2,400 similar lawsuits pending. This creates legal uncertainty and potential financial liability, which could negatively impact the stock.

    This is a new legal development that introduces significant risk and could lead to further payouts.

  • Competitive pressure in cardiovascular Johnson & Johnson's MedTech cardiovascular segment grew only 3.1%, and Abiomed declined 2% amid physician caution. This suggests a challenging environment for Medtronic's cardiovascular business, potentially limiting growth.

    This is a new competitive signal that highlights potential headwinds for Medtronic's cardiovascular sales.

July 2026
▲3▼1

Medtronic advances on reimbursement, AI surgery, and acquisitions

  • Permanent reimbursement codes proposed for renal denervation The AMA proposed permanent Category I codes for renal denervation, which would make it easier for hospitals to get paid for Medtronic's Symplicity Spyral blood-pressure treatment. That removes a big question mark over adoption, so more patients could get the therapy and Medtronic's sales could rise.

    This is a new regulatory catalyst that directly addresses a key overhang on Medtronic's RDN business.

  • Completes SPR Therapeutics acquisition for non-opioid pain care Medtronic finished buying SPR Therapeutics, adding a minimally invasive nerve-stimulation system to its pain portfolio. This expands its offerings in earlier-stage pain treatment and positions it as a more complete partner for pain clinics, potentially boosting future revenue.

    This is a new acquisition that expands Medtronic's pain therapy business and competitive position.

  • Unveils AI-native surgical platform and FDA-cleared AI app Medtronic launched Touch Surgery Aide, an AI computing platform for real-time surgical support, and received FDA clearance for Instrument Exit Point, its first real-time AI app for robotic surgery. This strengthens its Hugo robot ecosystem and could drive adoption and sales.

    This is a new product launch and regulatory clearance that enhances Medtronic's surgical robotics technology.

  • Class II recall of Octopus 4 devices Medtronic recalled 590 Octopus 4 Tissue Stabilizer devices due to an assembly issue. While the recall is small, it highlights quality-control challenges and could make some analysts more cautious about execution, potentially weighing on the stock.

    This is a new negative event that could affect investor sentiment on quality control.

▲3▼1

Medtronic advances on reimbursement, AI surgery, and acquisitions

  • Permanent reimbursement codes proposed for renal denervation The AMA proposed permanent Category I codes for renal denervation, which would make it easier for hospitals to get paid for Medtronic's Symplicity Spyral blood-pressure treatment. That removes a big question mark over adoption, so more patients could get the therapy and Medtronic's sales could rise.

    This is a new regulatory catalyst that directly addresses a key overhang on Medtronic's RDN business.

  • Completes SPR Therapeutics acquisition for non-opioid pain care Medtronic finished buying SPR Therapeutics, adding a minimally invasive nerve-stimulation system to its pain portfolio. This expands its offerings in earlier-stage pain treatment and positions it as a more complete partner for pain clinics, potentially boosting future revenue.

    This is a new acquisition that expands Medtronic's pain therapy business and competitive position.

  • Unveils AI-native surgical platform and FDA-cleared AI app Medtronic launched Touch Surgery Aide, an AI computing platform for real-time surgical support, and received FDA clearance for Instrument Exit Point, its first real-time AI app for robotic surgery. This strengthens its Hugo robot ecosystem and could drive adoption and sales.

    This is a new product launch and regulatory clearance that enhances Medtronic's surgical robotics technology.

  • Class II recall of Octopus 4 devices Medtronic recalled 590 Octopus 4 Tissue Stabilizer devices due to an assembly issue. While the recall is small, it highlights quality-control challenges and could make some analysts more cautious about execution, potentially weighing on the stock.

    This is a new negative event that could affect investor sentiment on quality control.

Q2 2026
▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

June 2026
▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

▲2

Medtronic gains on rival stumbles, acquisitions, and AI push

  • Competitor weakness in electrophysiology Boston Scientific's 2026 guidance missed expectations, with its electrophysiology growth slowing. Analysts say Medtronic may be taking market share in that heart-rhythm device business, which would lift Medtronic's sales and support its stock price.

    Shows a real competitive win that can boost Medtronic's revenue and investor sentiment.

  • Completes $550 million Scientia Vascular acquisition Medtronic finished buying Scientia Vascular for $550 million, adding specialized guidewires and catheters for brain blood vessels. The deal slightly lowers earnings per share in fiscal 2027 but is expected to add to earnings after that, strengthening its neurovascular business.

    A concrete capital move that expands a key product line and has a clear, if delayed, financial benefit.

  • Tariff hit lowered but still a growing cost Medtronic's CEO cut the expected tariff cost for fiscal 2027 to $250 million from $300 million, thanks to supply-chain changes. But tariffs remain a real and rising expense, and new U.S. tariff threats could force another rethink. Strong growth in heart ablation and other units helps offset the pressure.

    Tariffs directly affect Medtronic's costs and profits, and the lowered estimate is a fresh update investors need to weigh.

  • Robotic surgery competition cuts both ways Jim Cramer warned that Intuitive Surgical now faces real competition from Medtronic's Hugo robot, which is positive for Medtronic. But a separate report says Intuitive's dominant position is getting stronger, with most surgeons trained on its system and hospitals reluctant to switch, making Hugo an alternative rather than a superior choice.

    Medtronic's surgical robot is a key growth bet, and the mixed signals on how well it can challenge Intuitive matter for future sales.

Stryker Corporation (SYK)

Q3 2026
▲3▼1

Stryker's strong Q2 beat offset by supply snag and joint replacement weakness

  • Q2 beat and raised guidance Stryker's Q2 sales rose 9.4% to $6.6B and adjusted EPS hit $3.69, beating expectations, prompting management to raise full-year guidance. This shows the core business is healthy and growing faster than expected.

    This is the main positive fundamental driver for the period, showing strong financial performance.

  • Mako robotics milestone and new product launch Mako robotics surpassed 2.5 million procedures, and Stryker launched the Mako RPS handheld knee system. These innovations strengthen Stryker's position in the growing healthcare robotics market and support future demand.

    Highlights technological leadership and new product momentum, key for long-term growth.

  • $100M defense contract and tech partnerships Stryker won a $100M defense contract and advanced acquisitions and Apple Vision Pro technology. This government validation and tech integration open new revenue streams and enhance Stryker's product offerings.

    Shows diversification and external validation, which can boost investor confidence.

  • Manufacturing issue and joint replacement weakness A manufacturing problem limiting inventory and new business is expected to persist into Q4, and joint replacement underperformed on seasonal patterns. These headwinds dragged shares down 7.7% and left SYK down 6.5% YTD.

    This is the main negative force that offset strong fundamentals and pressured the stock price.

August 2026
▲3▼1

Stryker's strong demand and new tech offset by supply and joint replacement setbacks

  • Q2 earnings beat with 9% organic growth and raised outlook Stryker reported 9% organic sales growth, adjusted EPS up 17.9% to $3.69, and margin expansion. Management narrowed full-year organic growth outlook to 8.3-9.3%. This shows the core business is healthy and supports a higher stock price.

    This is the fundamental earnings result that anchors the period's positive momentum.

  • $100 million defense contract modification won Stryker's sales unit won a $100 million contract modification from the US Defense Logistics Agency. This adds incremental revenue and validates its products with a key government customer, giving the stock a short-term boost.

    A concrete new contract that adds demand and supports the stock.

  • Mako robotics surpasses 2.5 million procedures; ZuriMED acquisition and Apple Vision Pro app advance Mako robotics hit 2.5 million procedures globally, showing strong adoption. Stryker also agreed to acquire ZuriMED for rotator cuff technology and completed the first hip arthroscopy using its FDA-cleared Apple Vision Pro app. These moves strengthen its long-term competitive position.

    Highlights innovation and strategic growth that drive future revenue and market share.

  • Supply chain and joint replacement woes drag shares down 7.7% At a healthcare conference, executives said a manufacturing problem continues to limit inventory and new business, now expected to persist into Q4. Joint replacement also underperformed on seasonal patterns. This overshadowed recent gains and pressured the stock.

    This is the major negative event that caused a sharp sell-off and reflects real operational challenges.

Latest
▲3▼1

Stryker's strong demand and new tech offset by supply and joint replacement setbacks

  • Q2 earnings beat with 9% organic growth and raised outlook Stryker reported 9% organic sales growth, adjusted EPS up 17.9% to $3.69, and margin expansion. Management narrowed full-year organic growth outlook to 8.3-9.3%. This shows the core business is healthy and supports a higher stock price.

    This is the fundamental earnings result that anchors the period's positive momentum.

  • $100 million defense contract modification won Stryker's sales unit won a $100 million contract modification from the US Defense Logistics Agency. This adds incremental revenue and validates its products with a key government customer, giving the stock a short-term boost.

    A concrete new contract that adds demand and supports the stock.

  • Mako robotics surpasses 2.5 million procedures; ZuriMED acquisition and Apple Vision Pro app advance Mako robotics hit 2.5 million procedures globally, showing strong adoption. Stryker also agreed to acquire ZuriMED for rotator cuff technology and completed the first hip arthroscopy using its FDA-cleared Apple Vision Pro app. These moves strengthen its long-term competitive position.

    Highlights innovation and strategic growth that drive future revenue and market share.

  • Supply chain and joint replacement woes drag shares down 7.7% At a healthcare conference, executives said a manufacturing problem continues to limit inventory and new business, now expected to persist into Q4. Joint replacement also underperformed on seasonal patterns. This overshadowed recent gains and pressured the stock.

    This is the major negative event that caused a sharp sell-off and reflects real operational challenges.

July 2026
▲3▼1

Stryker's Q2 Beat and Raised Outlook Overshadowed by Post-Earnings Selloff

  • Q2 Beat and Raised 2026 Guidance Stryker reported Q2 sales of $6.6B (up 9.4%) and adjusted EPS of $3.69, beating estimates, and raised its full-year 2026 outlook. This shows the business is recovering strongly from the cyberattack and supports a higher stock price over time.

    This is the core fundamental news that answers why SYK is moving and what drives its value.

  • Shares Drop 6.4% After Earnings Despite Beat Even though results beat expectations, Stryker shares fell 6.4% after the report, leaving the stock down 6.5% year-to-date and at a 23% discount to one fair-value estimate. This shows investors were disappointed by something beyond the headline numbers, creating near-term price pressure.

    This explains the immediate negative price reaction and the current valuation gap, which is central to why the stock is moving now.

  • Mako RPS Handheld Robotic Knee System Launched in U.S. Stryker launched Mako RPS, a handheld robotic knee replacement system, in the U.S. This extends its robotics franchise into a new form factor, potentially broadening adoption and reinforcing the long-term growth story that supports the stock.

    This is a new product catalyst that could drive future demand and investor enthusiasm for SYK.

  • Rotation into High-Quality Healthcare Names Investor Sarat Sethi highlighted a rotation into cash-flow-generating healthcare companies like Stryker, noting the sector's S&P 500 weighting is at an all-time low. This suggests growing investor demand for SYK shares as money moves out of expensive tech.

    This points to a broader market shift that could lift SYK's stock price through increased demand.

▲3▼1

Stryker's Q2 Beat and Raised Outlook Overshadowed by Post-Earnings Selloff

  • Q2 Beat and Raised 2026 Guidance Stryker reported Q2 sales of $6.6B (up 9.4%) and adjusted EPS of $3.69, beating estimates, and raised its full-year 2026 outlook. This shows the business is recovering strongly from the cyberattack and supports a higher stock price over time.

    This is the core fundamental news that answers why SYK is moving and what drives its value.

  • Shares Drop 6.4% After Earnings Despite Beat Even though results beat expectations, Stryker shares fell 6.4% after the report, leaving the stock down 6.5% year-to-date and at a 23% discount to one fair-value estimate. This shows investors were disappointed by something beyond the headline numbers, creating near-term price pressure.

    This explains the immediate negative price reaction and the current valuation gap, which is central to why the stock is moving now.

  • Mako RPS Handheld Robotic Knee System Launched in U.S. Stryker launched Mako RPS, a handheld robotic knee replacement system, in the U.S. This extends its robotics franchise into a new form factor, potentially broadening adoption and reinforcing the long-term growth story that supports the stock.

    This is a new product catalyst that could drive future demand and investor enthusiasm for SYK.

  • Rotation into High-Quality Healthcare Names Investor Sarat Sethi highlighted a rotation into cash-flow-generating healthcare companies like Stryker, noting the sector's S&P 500 weighting is at an all-time low. This suggests growing investor demand for SYK shares as money moves out of expensive tech.

    This points to a broader market shift that could lift SYK's stock price through increased demand.

Q2 2026
▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

  • Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.

    This is the core negative event that explains the recent stock decline and is central to the question.

  • Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.

    Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.

  • Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.

    This positive counterweight shows underlying financial health and management confidence, which could support the stock.

  • Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.

    This highlights a long-term growth driver that could offset near-term headwinds and attract investors.

June 2026
▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

  • Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.

    This is the core negative event that explains the recent stock decline and is central to the question.

  • Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.

    Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.

  • Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.

    This positive counterweight shows underlying financial health and management confidence, which could support the stock.

  • Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.

    This highlights a long-term growth driver that could offset near-term headwinds and attract investors.

▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

  • Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.

    This is the core negative event that explains the recent stock decline and is central to the question.

  • Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.

    Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.

  • Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.

    This positive counterweight shows underlying financial health and management confidence, which could support the stock.

  • Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.

    This highlights a long-term growth driver that could offset near-term headwinds and attract investors.

© 2026 MarketIVWhy